Immune checkpoint inhibitors such as PD-1 and CTLA-4 monoclonal antibodies have transformed cancer therapy. Unlike small-molecule drugs, these agents exhibit target-mediated, time-varying clearance and prolonged half-lives. Their pharmacokinetics are influenced by complex interactions between disease biology, immune dynamics, and host-related factors. Therapeutic drug monitoring is being explored to better understand exposure–response relationships in selected populations. Think you know how monoclonal antibodies behave? Take this quick question and test your immunotherapy pharmacology instincts.
(Scroll down to answer the question) ##References## LaFleur MW, Muroyama Y, Drake CG, Sharpe AH. Inhibitors of the PD-1 Pathway in Tumor Therapy. J Immunol. 2018 Jan 15;200(2):375-383. Huang AC, Postow MA, Orlowski RJ, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1…
